Search
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalPEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529]. … PEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein.
Categories: Compounds used in a research, industrial, or household settingProducts: ADYNOVATE 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, ADYNOVATE 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTIONElranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb,[A261060] each of which contributes one heavy chain and one
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators. … Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L44918,L44948] It received a similar approval in the EU in September 2023. … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897].
Categories: Drugs Used in DiabetesNeisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalNeisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused … It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5MLRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions.
Categories: Drugs for Obstructive Airway DiseasesUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigationalallowing for administration in a one-hour infusion twice-a-year following the starting dose. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigational[A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … Vepdegestrant is a potent, selective, and orally bioavailable PROteolysis TArgeting Chimera (PROTAC) small molecule estrogen receptor (ER) degrader.